Castleark Management’s ANI Pharmaceuticals ANIP Stock Holding History

Castleark Management’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-67,020	Closed	-$3.89M	–	285
2023 Q3	$3.89M	Buy	+67,020	New	+$3.87M	0.2%	123
2016 Q4	–	Sell	-100,615	Closed	-$6.68M	–	374
2016 Q3	$6.68M	Buy	+100,615	New	+$6.29M	0.2%	157
2015 Q2	–	Sell	-154,401	Closed	-$9.66M	–	371
2015 Q1	$9.66M	Buy	154,401 +16,500	+12%	+$1M	0.23%	137
2014 Q4	$7.78M	Sell	137,901 -41,394	-23%	-$1.82M	0.2%	135
2014 Q3	$5.62M	Sell	179,295 -2,300	-1%	-$68.9K	0.16%	147
2014 Q2	$6.25M	Buy	181,595 +2,300	+1%	+$72.1K	0.17%	138
2014 Q1	$5.62M	Buy	+179,295	New	+$4.76M	0.16%	147

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GACM

Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

RIM

Ranger Investment Management Dallas, Texas $1.58B AUM 51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Castleark Management's ANIP Position: Q4 2023 in Review

Castleark Management sold out of ANI Pharmaceuticals (ANIP) in Q4 2023, closing a stake of 67,020 shares — an estimated $3.89M sold.

Castleark Management first reported a position in ANIP in Q1 2014 and held it in 7 quarters. The position peaked at $9.66M in Q1 2015. 181 funds tracked by Wall St. Rank hold ANIP as of Q4 2023.

Castleark Management reported no remaining ANI Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Castleark Management sold 67,020 ANI Pharmaceuticals shares in Q4 2023, an estimated $3.89M.
Castleark Management first reported a position in ANI Pharmaceuticals in Q1 2014 and held it in 7 quarters.
Castleark Management's ANI Pharmaceuticals position peaked at $9.66M in Q1 2015.
181 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q4 2023.

Based on Castleark Management's 13F filing for Q4 2023, filed 15 Feb 2024.